Feb 14 (Reuters) - Australia's CSL Ltd (CSL) reported a 10% jump in its first-half profit on Tuesday, as an uptick in blood plasma collections and the acquisition of Swiss drugmaker Vifor Pharma AG boosted its bottomline.
The biotech giant said its underlying net profit after tax for the half-year ended Dec. 31 was $1.96 billion on a constant currency basis, higher than $1.72 billion logged last year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$198.37 |
Change
0.030(0.02%) |
Mkt cap ! $96.23B | |||
| Open | High | Low | Value | Volume |
| $200.98 | $203.69 | $198.37 | $647.4M | 3.086M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 428 | $198.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $198.40 | 360 | 2 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| CSL (ASX) Chart |